Companies › Sunshine Guojian Pharmaceutical (Shanghai)
8 active drug programs in 13 registered trials: 6 Phase 3, 4 Phase 2, 3 Phase 1; Immunology, Respiratory, Oncology, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 608 | – | Phase 3 | Ankylosing Spondylitis; Axial Spondyloarthritis | Jan 2027 |
| 610 | – | Phase 3 | Asthma | Feb 2027 |
| 611 | – | Phase 3 | Sinusitis; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive (COPD) | Sep 2027 |
| SSGJ-707 bispecific antibody | – | Phase 2 | Metastatic Colorectal Cancer | Jun 2027 |
| 627 | – | Phase 2 | Ulcerative Colitis (UC) | Feb 2029 |
| SSGJ-705 anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 1 | Locally Advanced, Recurrent or Metastatic Malignancies | Dec 2026 |
| SSGJ-716 | – | Phase 1 | AD | Aug 2027 |
| 626 | – | Phase 1 | Systemic Lupus Erythematosus (SLE) | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06222671 | 608 | Phase 2 | Axial Spondyloarthritis | Immunology | Sep 2025 |
| NCT06639295 | 611 | Phase 3 | Sinusitis | Respiratory | Dec 2025 |
| NCT06390774 | SSGJ-705 | Phase 1 | Locally Advanced, Recurrent or Metastatic Malignancies | Oncology | Dec 2026 |
| NCT07261644 | 608 | Phase 3 | Ankylosing Spondylitis | Immunology | Jan 2027 |
| NCT06323213 | 610 | Phase 3 | Asthma | Respiratory | Feb 2027 |
| NCT06680947 | 610 | Phase 2 | Asthma | Respiratory | Feb 2027 |
| NCT06493760 | SSGJ-707 | Phase 2 | Metastatic Colorectal Cancer | Oncology | Jun 2027 |
| NCT07693738 | SSGJ-716 | Phase 1 | AD | Neurology | Aug 2027 |
| NCT07767253 | 611 | Phase 3 | Dermatitis, Atopic | Immunology | Sep 2027 |
| NCT07042126 | 611 | Phase 3 | Dermatitis, Atopic | Immunology | Sep 2027 |
| NCT07185269 | 626 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Aug 2028 |
| NCT07039669 | 611 | Phase 3 | Pulmonary Disease, Chronic Obstructive (COPD) | Respiratory | Sep 2028 |
| NCT07507513 | 627 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Feb 2029 |
Guangdong Hengrui Pharmaceutical Sun Pharmaceutical Industries Teva Branded Pharmaceutical Products R&D Chong Kun Dang Pharmaceutical DualityBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.